Table 2.
Consistency between baseline and follow-up QFT-GIT stratified by TST
| Follow-up QFT-GIT | ||||
|---|---|---|---|---|
| Baseline QFT-GIT | Positive (n = 15) n (%) |
Negative (n = 163) n (%) |
Agreement | |
| All subjects* (n = 178) |
Positive (n = 18) |
12 (6.7) |
6 (3.4) |
Raw = 94.9% κ = 0.70# |
| Negative (n = 160) | 3 (1.7) | 157 (88.2) | ||
| Positive prior TST (n = 54) |
Positive (n = 9) |
9 (16.7) |
0 |
Raw = 100% κ = 1.0# |
| Negative (n = 45) | 0 | 45 (83.3) | ||
| Recent TST > 5 mm (n = 51) |
Positive (n = 10) |
9 (17.6) |
1 (2.0) |
Raw = 94.1% κ = 0.82# |
| Negative (n = 41) | 2 (3.9) | 39 (76.5) | ||
| Recent TST ≥ 10 mm (n = 44) |
Positive (n = 10) |
9 (20.5) |
1 (2.3) |
Raw = 93.2% κ = 0.81# |
| Negative (n = 34) | 2 (4.5) | 32 (72.7) | ||
*Four individuals with indeterminate QFT-GIT results were excluded from this analysis. #p < 0.0001, each. QFT-GIT = QuantiFERON®-TB Gold In-Tube. TST = tuberculin skin test.